Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 1/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 6/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.32 |
| ▸ | CA2 | P00918 | 6/20 | 0.32 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30990531 | 0.81 | KDM4E (0.63) | KDM4EASPHKDM8KMO | |
| SCHEMBL15060252 | 0.81 | KDM4E (0.63) | KDM4EASPHKDM8KMO | |
| SCHEMBL21561868 | 0.79 | KDM4E (0.43) | KDM4EASPHKDM8KMOGCK | |
| Lithium Ion SCHEMBL694807 | 0.79 | DHODH (0.34) | KDM4EASPHKDM8KMOCA1 | |
| SCHEMBL2065683 | 0.79 | KDM4E (0.61) | KDM4EASPHKDM8KMO | |
| SCHEMBL2067513 | 0.79 | L3MBTL1 (0.45) | KDM4EASPHKDM8GCKSSTR4 | |
| SCHEMBL29918922 | 0.79 | L3MBTL1 (0.45) | KDM4EASPHKDM8GCKSSTR4 | |
| Potassium Ion SCHEMBL29039878 | 0.77 | DAO (0.35) | KDM4EASPHKDM8KMOCA1 | |
| Zinc Ion SCHEMBL31116884 | 0.76 | DHODH (0.34) | KDM4EASPHKDM8KMOCA1 | |
| Zinc Ion SCHEMBL28582478 | 0.76 | KDM4E (0.35) | KDM4EASPHKDM8KMOCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099794-B1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| CN-101652363-B | Thiazolyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-04-17 | — | — | CN | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| CN-101652363-A | Thiazolyl compounds as kinase inhibitor | SQUIBB BRISTOL MYERS CO US | 2010-02-17 | — | — | CN | disclosed |
| EP-2099794-A2 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008079873-A2 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | ERBB2, TEC, TTBK1 | KDM4E 2238/4885ASPH 1250/4885KDM8 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.